The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death

Current Alzheimer Research

Volumn 2, Issue 4, 2005, Pages 389-402

  LeBlanc, Andrea C ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer disease; Apoptosis; Caspase 6; Caspases; Neurodegeneration; Neuronal cell death

Indexed keywords

CALSENILIN; CASPASE; CASPASE 11; CASPASE 14; CASPASE 2; CASPASE 3; CASPASE 5; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; INTERLEUKIN 1BETA CONVERTING ENZYME; PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; APOPTOSIS; AUTOPHAGY; CELL DEATH; CELL ORGANELLE; COGNITIVE DEFECT; CYTOSKELETON; DISEASE COURSE; ENTORHINAL CORTEX; ENZYME ACTIVATION; HIPPOCAMPUS; HUMAN; IMMUNOCYTOCHEMISTRY; NERVE DEGENERATION; NEURITE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; CASPASES; DEMENTIA; HUMANS; MODELS, NEUROLOGICAL; NERVE DEGENERATION; NEURONS; SYNAPSES;

EID: 24644453571     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720505774330573     Document Type: Review

References (145)

1. Selkoe D. Alzheimer's Disease: Genotypes, phenotype and treatments. Science 275: 630-631 (1997).
2. Mudher A and Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 25: 22-26 (2002).
3. Johnson EM. Possible role of neuronal apoptosis in Alzheimer's disease. Neurobiol. Aging 15: 5187-5189 (1994).
4. Su J, Anderson A, Cummings B and Cotman C. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neurorep. 5: 2529-2533 (1994).
5. LeBlanc AC. Apoptosis and Alzheimer's disease. In: 'Apoptosis and Alzheimer's disease.'(Ed:WWaR Tanzi), Humana Press Inc., Totowa, NJ, 57-71 (1996).
6. Terry RD. Cell death or synaptic loss in Alzheimer disease. J Neuropathol Exp Neurol 59: 1118-1119 (2000).
7. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW and Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58: 1395-1402 (2001).
8. Hof PR, Bussiere T, Gold G, Kovari E, Giannakopoulos P, Bouras C, et al. Stereologic evidence for persistence of viable neurons in layer II of the entorhinal cortex and the CA1 field in Alzheimer disease. J Neuropathol Exp Neurol 62: 55-67 (2003).
9. Kordower JH, Chu Y, Stebbins GT, DeKosky ST, Cochran EJ, Bennett D, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 49: 202-213 (2001).
10. Gomez-Isla T, Hollister R, West H, Mui S, Growdon J, Petersen R, et al. Neuronal loss correlated with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41: 17-24 (1996).
11. West MJ, Coleman PD, Flood DG and Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344: 769-772 (1994).
12. Kril JJ, Patel S, Harding AJ and Halliday GM. Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol (Berl) 103: 370-376 (2002).
13. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurol. 60: 1495-1500 (2003).
14. Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J and Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol 57: 675-680 (2000).
15. Simic G, Kostovic I, Winblad B and Bogdanovic N. Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J Comp Neurol 379: 482-494 (1997).
16. West MJ. Regionally specific loss of neurons in the aging human hippocampus. Neurobiol Aging 14: 287-293 (1993).
17. Morrison J and Hof P. Life and death of neurons in the aging brain. Science 278: 412-419 (1997).
18. Bussiere T, Gold G, Kovari E, Giannakopoulos P, Bouras C, Perl DP, et al. Stereologic analysis of neurofibrillary tangle formation in prefrontal cortex area 9 in aging and Alzheimer's disease. Neurosci. 117: 577-592 (2003).
19. Bussiere T, Giannakopoulos P, Bouras C, Perl DP, Morrison JH and Hof PR. Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: Stereologic analysis of prefrontal cortex area 9. J Comp Neurol 463: 281-302 (2003).
20. Zarow C, Lyness SA, Mortimer JA and Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60: 337-341 (2003).
21. Kerr JF, Wyllie AH and Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257 (1972).
22. Wyllie AH, Kerr JFR and Currie AR. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68: 251-306 (1980).
23. Ferri KF and Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 3: E255-263 (2001).
24. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA and Kordower JH. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol 158: 469-490 (1999).
25. Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol. 89: 35-41 (1995).
26. Stadelmann C, Bruck W, Bancher C, Jellinger K and Lassmann H. Alzheimer Disease: DNA fragmentation indicates increased neuronal vulnerability, but no apoptosis. J. Neuropathol. Exp. Neurol. 57: 456-464 (1998).
27. Broe M, Shepherd CE, Milward EA and Halliday GM. Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol (Berl) 101: 616-624 (2001).
28. Mullaart E, Boerrigter M, Ravid R, Swabb D and Vijg J. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol. Aging 11: 169-173 (1990).
29. Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker EB, et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neurorep. 6: 1053-1057 (1995).
30. Lucassen PJ, Chung WC, Kamphorst W and Swaab DF. DNA damage distribution in the human brain as shown by in situ end labeling; area-specific differences in aging and Alzheimer disease in the absence of apoptotic morphology. J Neuropathol Exp Neurol 56: 887-900 (1997).
31. Troncoso JC, Sukhov RR, Kawas CH and Koliatsos VE. In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: correlations with senile plaques and disease progression. J Neuropathol Exp Neurol 55: 1134-1142 (1996).
32. Smale G, Nichols NR, Brady DR, Finch CE and Horton WE, Jr. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 133: 225-230 (1995).
33. Overmyer M, Kraszpulski M, Helisalmi S, Soininen H and Alafuzoff I. DNA fragmentation, gliosis and histological hallmarks of Alzheimer's disease. Acta Neuropathol (Berl) 100: 681-687 (2000).
34. Colurso GJ, Nilson JE and Vervoort LG. Quantitative assessment of DNA fragmentation and beta-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease. Life Sci 73: 1795-1803 (2003).
35. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9: 459-470. (2002).
36. Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasula SM, Alnemri ES, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 429: 75-79 (2004).
37. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, et al. A unified model for apical caspase activation. Mol Cell 11: 529-541 (2003).
38. Kaufmann SH and Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 11: 526-534 (2001).
39. Pompl PN, Yemul S, Xiang Z, Ho L, Haroutunian V, Purohit D, et al. Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease. Arch Neurol 60: 369-376 (2003).
40. Engidawork E, Gulesserian T, Yoo BC, Cairns N and Lubec G. Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 281: 84-93. (2001).
41. Raina AK, Hochman A, Zhu X, Rottkamp CA, Nunomura A, Siedlak SL, et al. Abortive apoptosis in Alzheimer's disease. Acta Neuropathol (Berl) 101: 305-310. (2001).
42. Rohn TT, Head E, Nesse WH, Cotman CW and Cribbs DH. Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol Dis 8: 1006-1016 (2001).
43. Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, Salvesen GS, Koo EH and Bredesen DE. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat. Med. 6: 397-404 (2000).
44. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW and Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 11: 341-354 (2002).
45. Zheng TS and Flavell RA. Divinations and surprises: genetic analysis of caspase function in mice. Exp Cell Res 256: 67-73 (2000).
46. Zheng T, Hunot S, Kuida K and Flavell R. Caspase knockouts: matters of life and death. Cell Death and Differentiation. 6: 1043-1053 (1999).
47. Shimohama S, Tanino H and Fujimoto S. Changes in caspase expression in Alzheimer's disease: Comparison with development and aging. Biochem. Biophys. Res. Comm. 256: 381-384 (1999).
48. Masliah E, Masliah M and Alford M. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer's disease. J. Neuropath. Exp. Neurol. 57: 1041-1052 (1998).
49. Selznick L, Holtzman D, Han B, Gokden M, Srinivasan A, Johnson E, et al. In situ immunodetection of neuronal caspase-3 activation in Alzheimer's disease. J. Neuropathol. and Exp. Neurol. 58: 1020-1026 (1999).
50. Stadelmann C, Deckwerth T, Srinivasan A, Bancher C, Bruck W, Jellinger K, et al. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Am. J. Pathol. 155: 1459-1466 (1999).
51. Su JH, Kesslak JP, Head E and Cotman CW. Caspase-cleaved amyloid precursor protein and activated caspase-3 are co-localized in the granules of granulovacuolar degeneration in Alzheimer's disease and Down's syndrome brain. Acta Neuropathol (Berl) 104: 1-6 (2002).
52. Su JH, Zhao M, Anderson AJ, Srinivasan A and Cotman CW. Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res 898: 350-357 (2001).
53. Gastard MC, Troncoso JC and Koliatsos VE. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol 54: 393-398 (2003).
54. LeBlanc AC, Liu H, Goodyer C, Bergeron C and Hammond J. Caspase-6 role in apoptosis of human neurons, amyloidogenesis and Alzheimer's Disease. J. Biol. Chem 274: 23426-23436. (1999).
55. Zhang Y and LeBlanc A. Microinjections as a method to study the specific role of pro-apoptotic proteins in neurons. In: 'Microinjections as a method to study the specific role of pro-apoptotic proteins in neurons.'(Ed:A LeBlanc), Humana Press, 83-106 (2002).
56. Zhang Y, Goodyer C and LeBlanc A. Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3, -6, -7, and -8. J Neurosci 20: 8384-8389. (2000).
57. Guo H, Albrecht* S, Bourdeau M, Petzke T, Bergeron C and Le-Blanc AC. Active Caspase-6 and Caspase-6 cleaved Tau in neuropil threads, neuritic plaques and neurofibrillary tangles of Alzheimer's Disease. Am. J. Pathol. 165: 523-531 (2004).
58. Ruchaud S, Korfali N, Villa P, Kottke TJ, Dingwall C, Kaufmann SH, et al. Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J 21: 1967-1977. (2002).
59. Martinon F and Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117: 561-574 (2004).
60. Desjardins P and Ledoux S. Expression of ced-3 and ced-9 homologs in Alzheimer's disease cerebral cortex. Neurosci. Lett. 244: 69-72 (1998).
61. Zhu SG, Sheng JG, Jones RA, Brewer MM, Zhou XQ, Mrak RE, et al. Increased interleukin-1beta converting enzyme expression and activity in Alzheimer disease. J Neuropathol Exp Neurol 58: 582-587 (1999).
62. Zhang WH, Wang X, Narayanan M, Zhang Y, Huo C, Reed JC, et al. Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death. Proc Natl Acad Sci USA 100: 16012-16017 (2003).
63. LeBlanc A. Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. J Neurosci 15: 7837-7846. (1995).
64. Barnes N, Li L, Yoshikawa K, Schwartz L, Oppenheim R and Milligan C. Increased production of amyloid precursor protein provides a substrate for caspase-in dying motorneurons. J. Neurosci. 18: 5869-5880 1998).
65. Gervais F, Xu D, Robertson G, Vaillancourt J, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's β-amyloid precursor protein and amyloidogenic β-peptide formation. Cell 97: 395-406 (1999).
66. Pellegrini L, Passer B, Tabaton M, Ganjei K and D'Adamio L. Alternative, non-secretase processing of Alzheimer's β-amyloid precursor protein during apoptosis by caspase-6 and -8. J. Biol. Chem. 274: 21011-21016 (1999).
67. Weidemann A, Paliga K, Durrwang U, Reinhard F, Zchuckert O, Evin G, et al. Proteolytic processing of the Alzheimer's Disease amyloid precursor protein within its cytoplasmic domain by caspase-like enzymes. J. Biol. Chem. 274: 5823-5829 (1999).
68. Soriano S, Lu DC, Chandra S, Pietrzik CU and Koo EH. The amyloidogenic pathway of amyloid precursor protein (APP) is independent of its cleavage by caspases. J Biol Chem 276: 29045-29050 (2001).
69. Tesco G, Koh YH and Tanzi RE. Caspase activation increases beta-amyloid generation independently of caspase cleavage of the beta-amyloid precursor protein (APP). J Biol Chem 278: 46074-46080 (2003).
70. Tesco G, Koh YH, Kim MJ and Tanzi RE. Stabilization of amyloidogenic secretases underlies increased Aβ generation following caspase activation. Society for Neurosci. 336.3: (2003).
71. Galvan V, Chen S, Lu D, Logvinova A, Goldsmith P, Koo EH, et al. Caspase cleavage of members of the amyloid precursor family of proteins. J Neurochem 82: 283-294 (2002).
72. Dumanchin-Njock C, Alves da Costa CA, Mercken L, Pradier L and Checler F. The caspase-derived C-terminal fragment of betaAPP induces caspase-independent toxicity and triggers selective increase of Abeta42 in mammalian cells. J Neurochem 78: 1153-1161 (2001).
73. Nishimura I, Uetsuki T, Kuwako K, Hara T, Kawakami T, Aimoto S, et al. Cell death induced by a caspase-cleaved transmembrane fragment of the Alzheimer amyloid precursor protein. Cell Death Differ 9: 199-208 (2002).
74. Zhao M, Su J, Head E and Cotman CW. Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease. Neurobiol Dis 14: 391-403 (2003).
75. Canu N, Dus L, Barbato C, Ciotti M, Brancolini C, Rinaldi A, et al. Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J. Neurosci. 18: 7061-7074 (1998).
76. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100: 10032-10037 (2003).
77. Chung CW, Song YH, Kim IK, Yoon WJ, Ryu BR, Jo DG, et al. Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis 8: 162-172 (2001).
78. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114: 121-130 (2004).
79. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421 (2003).
80. Choi EK, Zaidi NF, Miller JS, Crowley AC, Merriam DE, Lilliehook C, et al. Calsenilin is a substrate for caspase-3 that preferentially interacts with the familial alzheimer's disease-associated c-terminal fragment of presenilin 2. J Biol Chem 276: 19197-19204. (2001).
81. Kim T, Pettingell W, Jung Y, Kovacs D and Tanzi R. Alternate cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science 277: 373-376 (1997).
82. Yang F, Sun X, Beech W, Teter B, Wu S, Sigel J, et al. Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and neurons and plaque microglia in Alzheimer's disease. Am. J. Pathol. 152: 379-389 (1998).
83. Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, Cotman CW, et al. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol 158: 189-198. (2001).
84. Sperandio S, Poksay K, De Belle I, Lafuente MJ, Liu B, Nasir J, et al. Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ 11: 1066-1075 (2004).
85. Cuervo AM. Autophagy: in sickness and in health. Trends in Cell Biol. 14: 70-77 (2004).
86. Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 304: 1500-1502 (2004).
87. Scheff SW and Price DA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging 24: 1029-1046 (2003).
88. Valtorta F, Pennuto M, Bonanomi D and Benfenati F. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis? Bioessays 26: 445-453 (2004).
89. Hamos J, DeGennaro L and Drachman D. Synaptic loss in Alzheimer's disease and other dementias. Neurol. 39: 355-361 (1989).
90. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580 (1991).
91. Masliah E, Alford M, DeTeresa R, Mallory M and Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 40: 759-766 (1996).
92. Heinonen O, Soininen H, Sorvari H, Kosunen O, Paljarvi L, Koivisto E, et al. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's Disease. Neurosci. 64: 375-384 (1995).
93. Qin S, Hu XY, Xu H and Zhou JN. Regional alteration of synapsin I in the hippocampal formation of Alzheimer's disease patients. Acta Neuropathol (Berl) 107: 209-215 (2004).
94. Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, et al. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis 12: 97-109 (2003).
95. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr., et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurol. 56: 127-129. (2001).
96. Coleman PD and Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 24: 1023-1027 (2003).
97. Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30: 572-580 (1991).
98. Tiraboschi P, Hansen LA, Alford M, Masliah E, Thai LJ and Corey-Bloom J. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurol. 55: 1278-1283. (2000).
99. Masliah E, Terry RD, Mallory M, Alford M and Hansen LA. Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am J Pathol 137: 1293-1297 (1990).
100. Mukaetova-Ladinska EB, Hurt J, Honer WG, Harrington CR and Wischik CM. Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics. Neurosci Lett 317: 161-165 (2002).
101. Gazzaley AH, Siegel SJ, Kordower JH, Mufson EJ and Morrison JH. Circuit-specific alterationsof N-methyl-D-aspartate receptor subunit 1 in the dentate gyrus of aged monkeys. Proc. Natl. Acad. Sci. USA 93: 3121-3125 (1996).
102. Gazzaley AH, Thakker MM, Hof PR and Morrison JH. Preserved number of entorhinal cortex layer II neurons in aged macaque monkeys. Neurobiol Aging 18: 549-553 (1997).
103. Caulin C, Salvesen GS and Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138: 1379-1394. (1997).
104. Byun Y, Chen F, Chang R, Trivedi M, Green KJ and Cryns VL. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ 8: 443-450 (2001).
105. Prasad S, Soldatenkov VA, Srinivasarao G and Dritschilo A. Intermediate filament proteins during carcinogenesis and apoptosis (Review). Int J Oncol 14: 563-570 (1999).
106. Chen F, Chang R, Trivedi M, Capetanaki Y and Cryns VL. Caspase proteolysis of desmin produces a dominant-negative inhibitor of intermediate filaments and promotes apoptosis. J Biol Chem 278: 6848-6853 (2003).
107. Foley JD, Rosenbaum H and Griep AE. Temporal regulation of VEID-7-amino-4-trifluoromethylcoumarin cleavage activity and caspase-6 correlates with organelle loss during lens development. J Biol Chem 279: 32142-32150 (2004).
108. Luo JJ, Wallace W, Riccioni T, Ingram DK, Roth GS and Kusiak JW. Death of PC 12 cells and hippocampal neurons induced by adenoviral-mediated FAD human amyloid precursor protein gene expression. J Neurosci Res 55: 629-642 (1999).
109. Zhao B, Chrest FJ, Horton WE, Jr., Sisodia SS and Kusiak JW. Expression of mutant amyloid precursor proteins induces apoptosis in PC12 cells. J Neurosci Res 47: 253-263 (1997).
110. McPhie DL, Coopersmith R, Hines-Peralta A, Chen Y, Ivins KJ, Manly SP, et al. DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J Neurosci 23: 6914-6927 (2003).
111. Niikura T, Yamada M, Chiba T, Aiso S, Matsuoka M and Nishimoto I. Characterization of V642I-AbetaPP-induced cytotoxicity in primary neurons. J Neurosci Res 77: 54-62 (2004).
112. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13: 1225-1240 (2004).
113. Guo Q, Sebastian L, Sopher BL, Miller MW, Ware CB, Martin GM, et al. Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation. J Neurochem 72: 1019-1029 (1999).
114. Weihl CC, Ghadge GD, Kennedy SG, Hay N, Miller RJ and Roos RP. Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. J Neurosci 19: 5360-5369 (1999).
115. Passer BJ, Pellegrini L, Vito P, Ganjei JK and D'Adamio L. Interaction of Alzheimer's presenilin-1 and presenilin-2 with Bcl-X(L). A potential role in modulating the threshold of cell death. J Biol Chem 274: 24007-24013 (1999).
116. Chan SL, Mayne M, Holden CP, Geiger JD and Mattson MP. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem 275: 18195-18200 (2000).
117. Kim JW, Chang TS, Lee JE, Huh SH, Yeon SW, Yang WS, et al Negative regulation of the SAPK/JNK signaling pathway by presenilin 1. J Cell Biol 153: 457-463 (2001).
118. Terra F, Czech C, Esclaire F, Elyaman W, Yardin C, Baclet MC, et al. Neurons overexpressing mutant presenilin-1 are more sensitive to apoptosis induced by endoplasmic reticulum-Golgi stress. J Neurosci Res 69: 530-539 (2002).
119. Xu X, Shi YC, Gao W, Mao G, Zhao G, Agrawal S, Chisolm GM, Sui D and Cui MZ. The novel presenilin-1-associated protein is a proapoptotic mitochondrial protein. J Biol Chem 277: 48913-48922 (2002).
120. Chan SL, Culmsee C, Haughey N, Klapper W and Mattson MP. Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12. Neurobiol Dis 11: 2-19 (2002).
121. Manczak M, Park BS, Jung Y and Reddy PH. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med 5: 147-162 (2004).
122. Wolozin B, Alexander P and Palacino J. Regulation of apoptosis by presenilin 1. Neurobiol Aging 19: S23-27 (1998).
123. Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, et al. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. Embo J 23: 2586-2596 (2004).
124. Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacana E, Sunderland T, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 274: 1710-1713 (1996).
125. Araki W, Yuasa K, Takeda S, Shirotani K, Takahashi K and Tabira T. Overexpression of presenilin-2 enhances apoptotic death of cultured cortical neurons. Ann N Y Acad Sci 920: 241-244 (2000).
126. Sun J, Li M, Han J and Gu J. Sensitization of differentiated PC12 cells to apoptosis by presenilin-2 is mediated by p38. Biochem Biophys Res Commun 287: 536-541 (2001).
127. Araki W, Yuasa K, Takeda S, Takeda K, Shirotani K, Takahashi K, et al. Pro-apoptotic effect of presenilin 2 (PS2) overexpression is associated with down-regulation of Bcl-2 in cultured neurons. J Neurochem 79: 1161-1168 (2001).
128. Zhang Y, McLaughlin R, Goodyer C and LeBlanc A. Selective Cytotoxicity of Intracellular Amyloid β Peptide1-42 through p53 and Bax in Cultured Primary Human Neurons. J. Cell Biol. 156: 519-529 (2002).
129. Gyure KA, Durham R, Stewart WF, Smialek JE and Troncoso JC. Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125: 489-492. (2001).
130. Wolvetang EJ, Bradfield OM, Hatzistavrou T, Crack PJ, Busciglio J, Kola I, et al. Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis. Neurobiol Dis 14: 349-356 (2003).
131. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97-100 (1998).
132. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94: 13287-13292 (1997).
133. Quon D, Wang Y, Catalano R, Scardina J, Murakami K and Cordell B. Formation of β-amyloid protein deposits in brains of transgenic mice. Nature 352: 239-241 (1991).
134. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaque formation in transgenic mice. Science 274: 99-102 (1996).
135. Hsiao K, Borcheldt D, Olson K, Johannsdottir R, Kitt C, Yunis W, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15: 1203-1218 (1995).
136. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid protein. Nature 373: 523-527 (1995).
137. Chishti MA, Yang DS, Janus C, Phinney AL, Home P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276: 21562-21570. (2001).
138. Lamb BT, Bardel KA, Kulnane LS, Anderson JJ, Holtz G, Wagner SL, et al. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat Neurosci 2: 695-697 (1999).
139. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 96: 3228-3233. (1999).
140. Irizarry MC, McNamara M, Fedorchak K, Hsiao K and Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CAl. J Neuropathol Exp Neurol 56: 965-973 (1997).
141. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17: 7053-7059 (1997).
142. Zhang F, Eckman C, Younkin S, Hsiao KH and Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci. 17: 7655-7661 (1997).
143. Higgins LS, Rodems JM, Catalano R and Cordell B. Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for B-APP751. Proc. Natl. Acad. Sci. USA 92: 4402-4406 (1995).
144. LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC and Jay G. The Alzheimer's A peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat. Gen. 9: 21-30 (1995).
145. Oddo S, Caccamo A, Kitazawa M, Tseng BP and LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24: 1063-1070 (2003).